RxDoctor Payments Data

William Manuel, MD

Internal Medicine · Houston, TXNPI 1992780118

Payments from drug & device makers

$714in general payments, 2019–2025

Across 27 payments — averaging $26.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$154
  • Lilly USA, LLC$140
  • Novo Nordisk$104
  • Gilead$96
  • Amgen$78
  • Amarin Pharma, Inc.$34
  • plus $108 from 6 others

What the payments were for

  • Food & beverage$714100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$714 in reported general payments places this provider in the 60th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$115,489
Medicare patients
150
Services billed
1,251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin11$37,925
OzempicSemaglutide18$23,156
RybelsusSemaglutide16$21,667
MounjaroTirzepatide21$21,299
TrulicityDulaglutide20$20,299
EliquisApixaban14$11,664
FarxigaDapagliflozin Propanediol15$7,565
VascepaIcosapent Ethyl13$6,538
Praluent PenAlirocumab11$6,222
Rosuvastatin Calcium226$2,264
SynthroidLevothyroxine Sodium16$1,653
Losartan Potassium169$1,506
PaxlovidNirmatrelvir/Ritonavir19$1,429
Levothyroxine Sodium94$1,067
Metoprolol Succinate58$1,014

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$104$44,82234 claims
Lilly USA, LLCMounjaro, Trulicity$140$41,59841 claims
PfizerEliquis, Paxlovid$30$13,09333 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →